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Stephen J. Walters2, Catherine Hewitt7, Martin Bland7, Dean A. Fergusson8, Jesse A. Berlin9, Doug Altman1,
Luke David Vale10 and Jonathan Alistair Cook1*
Abstract
Background: A key step in the design of a randomised controlled trial is the estimation of the number of participants
needed. The most common approach is to specify a target difference in the primary outcome between the randomised
groups and then estimate the corresponding sample size. The sample size is chosen to provide reassurance that the trial
will have high statistical power to detect the target difference at the planned statistical significance level. Alternative
approaches are also available, though most still require specification of a target difference.
The sample size has many implications for the conduct of the study, as well as incurring scientific and ethical aspects.
Despite the critical role of the target difference for the primary outcome in the design of a randomised controlled trial
(RCT), the manner in which it is determined has received little attention. This article reports the development of the
DELTA2 guidance on the specification and reporting of the target difference for the primary outcome in a sample size
calculation for a RCT.
Methods: The DELTA2 (Difference ELicitation in TriAls) project has five components comprising systematic literature
reviews of recent methodological developments (stage 1) and existing funder guidance (stage 2), a Delphi
study (stage 3), a 2-day consensus meeting bringing together researchers, funders and patient representatives
(stage 4), and the preparation and dissemination of a guidance document (stage 5).
Results: The project started in April 2016. The literature search identified 28 articles of methodological developments
relevant to a method for specifying a target difference. A Delphi study involving 69 participants, along with a 2-day
consensus meeting were conducted. In addition, further engagement sessions were held at two international
conferences. The main guidance text was finalised on April 18, 2018, after revision informed by feedback gathered from
stages 2 and 3 and from funder representatives.
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Discussion: The DELTA2 Delphi study identified a number of areas (such as practical recommendations and examples,
greater coverage of different trial designs and statistical approaches) of particular interest amongst stakeholders which
new guidance was desired to meet. New relevant references were identified by the review. Such findings influenced
the scope, drafting and revision of the guidance. While not all suggestions could be accommodated, it is hoped that
the process has led to a more useful and practical document.
Keywords: Target difference, Clinically important difference, Sample size, Guidance, Randomised trial, Effect size, Delphi
Background
Deciding upon an appropriate sample size is a key part of
designing a randomised controlled trial (RCT) [1]. A sam-
ple size calculation is typically carried out. Too small a
sample size could result in a difference being overlooked,
whilst a sample size which is too large could be a waste of
resources and also lead to spurious findings [2].
In the healthcare setting, the majority of RCTs adopt a
conventional approach (Neyman–Pearson) to determin-
ing the sample size. With this approach, the sample size
required for a RCT depends upon the magnitude of dif-
ference to be detected (the ‘target difference’) along with
the risk of reporting a difference when none exists (type
I error) and the risk of reporting no difference when a
difference of the specified magnitude does exist (type II
error). The sample size is highly dependent upon the
magnitude of difference, the target difference or effect
size, as it has often somewhat imprecisely been referred
to. For example, reducing the target difference by a half,
quadruples the sample size in a two-arm parallel-group
trial with 1:1 allocation and a continuous outcome, which
is assumed to be normally distributed [3].
Until recently [2], little has been published looking at
methods to inform the choice of target difference. Initial
guidance was prepared for standard (non-adaptive su-
periority two-arm parallel group) trials to be designed
and analysed according to the Neyman–Pearson ap-
proach [4]. However, that guidance does not cover trials
of different hypotheses (i.e. equivalence/non-inferiority
trials), any complex designs (e.g. multi-arm or adaptive
trials), or other alternative statistical approaches (such as
Bayesian and precision based). It is clear that limitations
in the scope and conception (as it was developed pri-
marily for researchers) of the initial DELTA guidance
means that it does not fully meet the needs of funders
and researchers. The DELTA2 project [5] sought to ad-
dress this gap. This paper reports on the development of
the DELTA2 guidance.
Aim and objectives
The DELTA2 project aimed to update and expand upon
the previous DELTA guidance for researchers and fun-
ders to assist in the determination and corresponding
reporting of the target difference (‘effect size’) when per-
forming a sample size calculation for a RCT.
The specific project objectives were:
1. To review existing guidance provided by funders
to researchers and scientific review panel/board
members
2. To identify key methodological developments
or changes in practice that have emerged since
undertaking the comprehensive DELTA review
[2, 6] and update the DELTA guidance
3. To determine the scope of guidance that would aid
researchers and address funders’ needs
4. To achieve consensus on what structured guidance
for choosing the target difference (effect size)
should comprise
5. To identify future research needs
To achieve these objectives, a five-stage project was
developed [5]. This publication briefly summarises the
methods of the project, before proceeding to presenting
the findings from stages 1–4, which informed the devel-
opment of the guidance.
Methods
A summary of the methods used in each stage are given
below. The final guidance is available [7] and has been sum-
marised in a companion paper (Cook JA, et al.: DELTA2
guidance on choosing the target difference and undertaking
and reporting the sample size calculation for a randomised
controlled trial - new guidance, forthcoming). The process
of developing the guidance is described below.
Stage 1 and 2. Identifying relevant literature and eliciting
expert opinion
Literature search
A systematic review was performed to identify recent publi-
cations detailing novel approaches to determining the tar-
get difference for a RCT. Publications were identified using
a systematic search within the PubMed database for articles
published after the DELTA review (January 1, 2011) and
March 31, 2016 [2, 6]. The search was restricted to journals
where previous relevant methodological work in this area
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had been published [2, 6], supplemented by other leading
journals in epidemiology, health economics, health research
methodology, statistics and trials. Full details of the search
strategy used can be found in Additional file 1.
In addition to the systematic review of publications, a
review of existing online guidance provided by funding
schemes and advisory bodies was performed.
Search for guidance
Guidance documents prepared by trial funding and advis-
ory bodies to assist applicants applying for funding for a
RCT were inspected for relevant text. Searches were car-
ried out for documents associated with UK trial funding
schemes run by the National Institute for Health Research
(NIHR), including Efficacy and Mechanism Evaluation
(EME), Health Technology Assessment (HTA), the Re-
search for Patient Benefit (RfPB) Programme, Programme
Grants for Applied Research (PGfAR), Public Health Re-
search (PHR), Invention for Innovation (i4i), and Health
Services and Delivery Research (HSDR), the Medical Re-
search Council (MRC) Developmental Pathway Funding
Scheme (DPFS), the Arthritis Research UK, the British
Heart Foundation (BHF), Cancer Research UK (CRUK)
(phase III clinical trial, new agent, population research),
and the Wellcome Trust (Health Challenge Innovation
Fund). The UK Health Research Authority's (HRA) docu-
mentation was searched. A search of guidance documents
provided by the NIHR Research Design Service (RDS) was
also performed. Similar searches were performed for lead-
ing international funding streams and regulatory agencies
(Agency for Healthcare Research and Quality (AHRQ),
Canadian Institutes of Health Research (CIHR), European
Commission Horizon 2020 (H2020), Food and Drug Ad-
ministration (FDA), Health Canada, National Health and
Medical Research Council (NHMRC), National Institutes
of Health (NIH), and Patient-Centered Outcomes Re-
search Institute (PCORI)). Information contained within
guidance for applicants applying for trial funding from
funders and research advisory bodies regarding the choice
of target difference was extracted.
Inclusion and exclusion criteria
The title and abstract of articles identified within the
PubMed database search were independently assessed by
two reviewers to identify publications worthy of further as-
sessment. The full-text of a publication deemed worthy of
further assessment was then analysed by a reviewer and in-
cluded if considered to report a development not already
encompassed within the previous DELTA review [2, 6].
Data extraction
Publications viewed to be of relevance were reviewed by
an expert reviewer and aspects of interest noted. Infor-
mation on undertaking a sample size calculation and the
target difference choice was identified within the web-
sites of trial funding and advisory bodies and the content
assessed by two reviewers. A third (content expert)
member of the team acted as arbiter for all disagree-
ments or where further content expertise was required.
Stage 3. Delphi study
A multi-round Delphi study was conducted with stake-
holders known to have an interest in the design of RCTs.
Participants were asked about what guidance was needed
on specifying the target difference in a RCT sample size
calculation. A 2-day consensus meeting and a one-off
stakeholder engagement session were embedded within
the Delphi study (stage 4; see below for details). Findings
from the first Delphi round were considered by the
2-day consensus meeting to aid construction of a draft
DELTA2 guidance document. A second-round question-
naire was sent with a hyperlink to the draft guidance
document. Views and comments on the draft guidance
overall, main body of the document, case studies, appen-
dices and references were requested. Round 1 and 2
questionnaires are available in Additional file 2.
A group of known methods experts, the inclusion of which
was informed by the DELTA review and findings from Stage
1, alongside representatives of key trial groups were invited
to participate in the Delphi study. Representatives for groups
including the UKCRC network of clinical trial units (CTUs),
the MRC Hubs for Trials Methodology Research (HTMRs),
NIHR/MRC/CRUK funding programme panels, the NIHR
statistics group and the NIHR RDS were contacted using
publicly available contact information and invited to partici-
pate. Participants comprised of one named individual per
group (unit, board, MRC HTMR, RDS centre or
programme; e.g. the director, chair or senior methodolo-
gist). These groups represent UK centres and networks of
excellence that undertake high-quality trials research.
As of July 1, 2016, there were 48 (fully or provision-
ally) registered CTUs, 5 MRC HTMRs and the 10 re-
gions in the NIHR RDS in England, and the Research
Design and Conduct Service in Wales.
Based upon the premise that a minimum of 30 partici-
pants would be required to participate in the Delphi
process, and assuming one-third of invitees would agree to
participate, it was felt that at least 90 invitations needed to
be made. Due to the arbitrary nature of this target, no strict
maximum was applied and 162 invitations were made.
Stage 4. Two-day consensus meeting and one-off
stakeholder engagement sessions
Two-day consensus meeting
Proposals as to the structure and content of the guidance,
put forward as part of the first round Delphi process, in
addition to literature developments and current guidance
practices were presented to 25 stakeholders in a face-to-
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face, 2-day meeting. Additionally, a number of participants
gave presentations that provided an overview of the use of
specific approaches and/or personal experience of working
in this area. Stakeholders, selected to cover a range of per-
spectives, areas of expertise and roles within RCT design,
discussed and refined the proposal for the guidance docu-
ment and reached a consensus on the format of the draft
guidance document.
One-off stakeholder engagement sessions
To gain a broader range of opinions, engagement sessions
were held at the Society for Clinical Trials (SCT) 37th An-
nual Meeting on May 17, 2016, Statisticians in the Pharma-
ceutical Industry (PSI) Conference on May 16, 2017, and
on the Joint Statistical Meetings (JSM) Conference on Au-
gust 1, 2017. Participants were invited to provide views on
the scope and structure of the guidance needed and to offer
constructive feedback on the draft guidance.
Stage 5. Publication of guidance documentation
The provisional guidance was drafted upon completion
of stages 1–4 and circulated amongst the DELTA2 mem-
bers and Delphi participants for comments. UK Funder
representatives will be asked to assess the guidance to
ensure the document meets funding panel requirements
and allow implementation of changes required for spe-
cific forms of publication.
Results
Stage 1. Systematic literature search results
The search identified 1395 potentially relevant reports
(Fig. 1). Following the screening of titles and abstracts, 73
Fig. 1 Flow diagram
Sones et al. Trials  (2018) 19:542 Page 4 of 11
publications were full text assessed. Of these, 28 were in-
cluded in the review as representing a development of one
of the previously identified seven broad method types
(Table 1 and Additional file 3). Minor developments were
identified for the health economic (including cost-utility and
value of information), opinion-seeking, pilot/preliminary
study and standardised effect size approaches. No new
methods were identified. Most developments (n = 17 arti-
cles) related to the use of variants of the value of informa-
tion approach.
Table 1 Included studies from literature review of methodological development in methods for specifying a target difference
Study Journal Method Methodological development
Hedayat 2015 Biometrics Anchor Variation in threshold-based approach to estimating the MID
Rouquette 2014 Journal of Clinical Epidemiology Anchor Use of item response model approach to calculate M(C)ID
estimate from anchor assessment
Zhang 2015 Journal of Clinical Epidemiology Anchor Assessment of expressing MID as absolute and relative difference
Hollingworth 2013 Clinical Trials HE (cost utility) Assessment of cost-utility-based sample size approaches
Chen MH 2013 Clinical Trials HE (VOI) VOI for multistage adaptive trials from industry perspective
Andronis 2016 Medical Decision making HE (VOI) Expected value of sample information variant estimator
Breeze 2015 Health economics HE (VOI) ENBS from pharmaceutical perspective using value-based pricing
Hall 2012 Medical Decision making HE (VOI) Expected net present value of sample information approach
Jalal 2015 Medical Decision making HE (VOI) Meta modelling approach to calculating the expected value of sample
information
Madan 2014 Medical Decision making HE (VOI) Efficient approach to calculating the expected value of partial perfect
information (applicable to calculating the expected value of sample
information)
Maroufy 2014 Journal of Biopharmaceutical
Statistics
HE (VOI) Method for calculating expected net gain of sampling
Mckenna 2011 Medical Decision making HE (VOI) Exploration of the role of value of sample information analysis
Menzies 2016 Medical Decision making HE (VOI) Expected value of sampling information estimator
Sadatsafavi 2013 Health economics HE (VOI) Expected value of sample information variant estimator
Streuten* 2013 Pharmacoeconomics HE (VOI) Comprehensive review of VOI methodological developments
Strong 2014 Medical Decision making HE (VOI) Meta modelling approach to calculating the expected value of sample
information
Welton 2014 Medical Decision making HE (VOI) Application of expected value of sampling information to a cluster trial
Welton 2015 Medical Decision making HE (VOI) ENBS accounting for heterogeneity in treatment effects
Willan 2011 Pharmacoeconomics HE (VOI) Framework for exploring the perspective of societal decision-maker
and industry
Willan 2012 Health economics HE (VOI) Accounting for between-study variation in value of information approach
Kirkby 2011 BMC Medical Research
Methodology
Opinion seeking Survey approach to estimate MCID in trial setting
Ross 2012 BMC Medical Research
Methodology
Opinion seeking Survey approach to estimate MCID with three treatment options
Chen H 2013 Clinical Trials Pilot/Preliminary
study
Comparison of approaches to using SD from preliminary study (e.g.
pilot or phase 2 study)
Fay 2013 Clinical Trials Pilot/Preliminary
study
Variation in approach to using SD from preliminary study (e.g. pilot
or phase 2 study)
Kirby 2015 Pharmaceutical statistics Pilot/Preliminary
study
Variation in approaches to discounting evidence from preliminary study
Sim 2012 Journal of Clinical Epidemiology Pilot/Preliminary
study
Inflation factor for pilot study SD estimate for use in trial sample size
calculation
Whitehead 2016 Statistics Method in Medical
Research
Pilot/Preliminary
study
Assessment of size of pilot study needed to inform main trial
Valentine 2016 JCE SES Alternative effect size metric proposed
*This review summarised a substantial number of variants/generalisations in the VOI methods applicable to the sample size calculation of a RCT
ENBS expected value of net benefit sampling, HE health economics, MID minimally important difference MCID minimal clinically important difference, SD standard
deviation, SES standardised effect size, VOI value of information
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A number of helpful review articles that summarise dif-
ferent methods and variations in application were identi-
fied; these covered willingness to pay [8, 9] and value of
information [10, 11] health economic based ap-
proaches, and estimation of the smallest worthwhile
difference formulation of a minimal clinically import-
ant difference, which covered anchor, distribution,
opinion-seeking and standardised effect size methods
[12]. Identified articles on relevant topics (e.g. that
address statistical aspects of sample size calculations
or an existing method but contain no new develop-
ment) were considered as potential references in the
guidance document irrespective of whether they were
included in this review.
Stage 2. Search for existing guidance
A search for guidance documentation on the websites for
the 15 trial funding and advisory bodies listed within the
Methodology section was performed (Additional file 4).
On the majority of websites, trial design guidance empha-
sised the need for applicants to provide sufficient detail to
justify the chosen sample size, often going on to discuss
techniques employed to calculate sample size but without
providing any details or guidance on how this should be
done. In particular, there was little specific guidance pro-
vided to assist researchers in specifying the target differ-
ence. The use of pilot/preliminary studies and ‘interim
data’ was noted with limited further comment.
Stage 3. Delphi study
Invitations to participate in the Delphi study were sent
(by email on July 29, 2016) to 58 methods experts along
with 104 named representatives of key trial groups (in-
cluding UKCRC network CTUs, the MRC HTMRs,
NIHR/MRC/CRUK funding programme panels, the
NIHR statistics group and the NIHR RDS). Of the 162
individuals invited to participate, responses were re-
ceived from 84 (52%), of whom 78 (48%) accepted the
invitation and 6 formally declined to participate. Ac-
ceptance of the invitation was allowed up to October
10, 2016 (the last acceptance was received on October
4, 2016).
The round 1 questionnaire was open for completion
between August 11 and October 10, 2016. Of the 78
experts and representatives who agreed to participate, 69
(88%) completed the Round 1 questionnaire once invited
by email whilst 9 did not complete it. The demographics
of those who ultimately participated in the Delphi study
are given in Table 2. Participants represented a range of
RCT roles, with design, analysis and evaluating funding
proposals well represented. The majority of participants
(57 of the 69 who completed Round 1; 83%) were pri-
marily affiliated with an academic institution, and the
majority of participants were from the UK (55 of the 69
who completed Round 1; 80%). Views on whether
specific topics and alternative designs (i.e. not a ‘stand-
ard’ two-arm, parallel-group design) should be covered
Table 2 Delphi participants’ demographics
Question Response Count (percentage of participants)
Your role in RCTs (select all that apply): Involved in analysis of RCTs 42 (61%)
Involved in RCT design (Collaborating Clinician) 7 (10%)
Involved in RCT design (Lead/Chief Investigator) 23 (33%)
Involved in RCT design (Statistician/Methodologist) 49 (71%)
Other (Please specify) 16 (23%)
Serves on a funding panel/board which evaluates
applications for RCT funding
43 (62%)
Primary RCT related affiliation: Academic institution 57 (83%)
Contract research organisation 2 (3%)
Funder of RCTs (e.g. NIHR in the UK or NIH in the US) 5 (7%)
Healthcare provider (e.g. NHS in the UK) 3 (4%)
Pharmaceutical/medical device company 2 (3%)
Where do you work? If you work across Europe
or Internationally please choose the category in
which the majority of your work is performed
Canada 3 (4%)
Ireland 1 (1%)
Other European Country 1 (1%)
UK 55 (80%)
US 9 (13%)
Australasia 0 (0%)
Other 0 (0%)
NHS National Health Service, NIH National Institutes of Health, NIHR National Institute for Health Research, RCT randomised controlled study
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within the guidance are given in Figs. 2 and 3. Delphi
participants showed strongest support (≥ 25%) for exten-
sive coverage on alternative research questions and
handling multiple primary outcomes. Across most topics
there was 50–70% support for proportionate coverage
except for mechanistic studies and public and patient
perspectives on the choice of the target difference.
Regarding alternative study designs, the strongest support
for extensive coverage was for adaptive designs, cluster
randomised trials and multi-arm trials (all > 25%). Across
all designs there was 50–60% support for proportionate
coverage.
A total of 56 free-text comments were made covering
personal views on specific topics, views on framing of
research questions, and the audience that should be tar-
geted for the guidance. Comments also included sugges-
tions for additional trial designs to cover, references and
case study topics.
The Round 2 questionnaire was open for completion
between September 1 and November 12, 2017. Only
participants who completed Round 1 were invited to par-
ticipate in Round 2 in which assessment of draft guide-
lines was required. Only two rounds were performed to fit
with the project timescale and progress. Of the 69 partici-
pants invited to participate in Round 2, 38 (55%) com-
pleted Round 2. Findings from the Round 2 questionnaire
are summarised in Fig. 4. Over 80% either ‘somewhat’ or
‘strongly’ agreed that the guidance was useful overall for
Fig. 2 Round 1 Delphi online questionnaire responses. Specific topics to address within target difference estimation guidance
Fig. 3 Round 1 Delphi online questionnaire responses. Alternative trial designs to address within target difference estimation guidance
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the recommendations, case studies and appendices; 21
suggestions for improving the main text were made, 11 re-
garding the case studies and 9 on the appendices. In
Round 2, 62 free-text comments were provided, which
again covered a range of suggestions for improving the
main text, adding an executive summary, improving the
signposting of sections, views on the case studies and ap-
pendices, additional references, raising the issue of esti-
mands, and personal views on various topics. Comments
made in Round 1 and 2 questionnaires along with feed-
back from Stage 4 led to a substantial number of changes
to the document prior to its finalisation. The most sub-
stantive being incorporating an executive summary and
increasing the number of case studies.
Stage 4. Two-day meeting and stakeholder engagement
An engagement session was held at SCT in May 2016,
where the project was introduced, and views on the
scope and broad content of the guidance were invited
through audience participation. Following this, a 2-day
workshop was held in Oxford on September 27–28,
2016, and involved 25 participants including CTU direc-
tors, study investigators, project funder representatives,
funding panel members, researchers with experts in
sample size methods, senior trial statisticians, and Public
and Patient Involvement (PPI) representatives. The
workshop included presentations of the findings from
the initial two stages of the project, the SCT engagement
session and Round 1 of the Delphi study, and focused
upon decisions relating to the scope and content of the
guidance. An initial structure for the first draft of the
guidance was developed in light of the findings from the
Round 1 questionnaire available at the time of the meet-
ing. A revised structure was agreed by participants at the
workshop. Drafting of individual sections was allocated
to individuals. The recommendations on conducting a
sample size calculation were initially drafted by JC. The
various sections were then developed into the first full
draft of the guidance by JC; this was circulated to all of
the DELTA2 project group for comment, with the draft
revised in light of these. An iterative process of com-
ments and revisions was followed until the final version
was agreed.
Subsequently, two further engagement sessions were
held at PSI and JSM conferences. At the time of the ses-
sion, the most current draft of the guidance was made
available to participants. Both within and post-meeting
feedback highlighted the need to consider the role of
estimands and the minimum (statistically) detectable
difference in the sample size calculation, leading to revi-
sions in the guidance document. There was broad con-
sensus, though not universal agreement, on the need for
such guidance and the main topics it needed to cover
from stakeholders across the various meetings and from
the Delphi study. Differences of opinion tended to be
about which topic needed to be covered and how
important it was that they were covered.
Stage 5. Finalisation, adaptation and dissemination
The draft guidance was reviewed by the representatives
of the project’s funders (MRC-NIHR Methodology Ad-
visory Group) on October 2, 2017. A number of revi-
sions were made in light of feedback received from the
advisory group and further feedback from the authors.
The revised text of the main guidance was finalised on
February 28, 2018. It was endorsed by the MRC-NIHR
Methodology Advisory Group on March 12, 2018, with
minor updating of references and the final version pro-
duced on April 18, 2017. Engagement with individual
funders and funding programmes for the best way to
Fig. 4 Round 2 Delphi online questionnaire responses
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utilise the guidance document and adapt to their needs
is ongoing.
Discussion
Overview
The target difference is arguably the key value in a
conventional sample size calculation but also the most
difficult to choose. The DELTA2 project sought to pro-
duce more detailed guidance for researchers and funder
representatives to aid researchers in making this choice
and funder representatives in assessing the choice made.
Building upon the DELTA guidance, a number of aspects
were explored through engagement with stakeholders
and the findings are summarised in this paper.
Decisions on scope and content
As part of the process, we explored uncertainty about
what methods for sample size determination should be
covered. In particular, the views on two methods (value
of information and standardised effect size-based ap-
proaches), which were included in the DELTA guidance,
were debated and the inclusion reconsidered. There was
general agreement that they should be included again
but in particular the distinctive nature of the value of
information approach required greater prominence. The
need for some consideration of alternative statistical
approaches (aside from the specification of the target
difference per se) was also relatively strong. This resulted
in specific appendices and boxes within the main guid-
ance text covering more common alternative statistical
methods and trial designs, and dealing with related as-
pects such as compliance analyses and missing data.
The need for more practical guidance was raised mul-
tiple times in various responses and in the engagement
sessions. This led to two main additions in the final guid-
ance document. First, 10 recommendations were made for
specifying the target difference and a list of corresponding
reporting items was included for when the conventional
sample size approach is used. It is hoped that this will go
some way to support researchers and funders undertaking
and assessing sample size calculations. It is recognised that
future adaptation to accommodate other study designs
and statistical approaches will be needed. Second, a num-
ber of case studies were included, reflecting different trial
designs and covering different conditions. Additional case
studies could be added over time to provide a more
complete coverage of the range of trial designs, statistical
approaches and methods for specifying the target differ-
ence. Overall, the DELTA2 guidance is more comprehen-
sive than the original DELTA guidance (and also more
detailed, with over 25,000 compared to around 4000
words). It covers a much broader range of trials and ap-
proaches, with more practical guidance about how to
undertake a sample size calculation for a RCT. A number
of areas for further research were identified. Addressing
these evidence gaps would help inform guidance for less
common statistical approaches and trial designs.
Strength and limitations
The main strength of this guidance lies in the extensive
preparatory work undertaken in both the DELTA2 pro-
ject and also the original DELTA work. The multiple
avenues for engagement with stakeholders represent an-
other strength, since this provided opportunities to so-
licit views on relevant topics and feedback on the draft
guidance to be expressed by various stakeholders. A
variety of methods were used to inform the development
of the guidance document, including systematic reviews
of the literature, a Delphi study using online question-
naires, engagement sessions with stakeholder groups and
a 2-day workshop.
Participants in the various stages of the project were
self-selected and may not be fully representative of all
stakeholders. In particular, despite several attempts,
there was limited involvement of industry statisticians
with the exception of the PSI stakeholder meeting, and
participants were mostly academic statisticians. Overall,
those involved were possibly more methodologically in-
terested than those who did not engage.
Timings of key meetings meant that flexibility was
needed in the conduct of the stages and they were not
carried out in a sequential manner as originally envi-
sioned. The Delphi study only had 69 participants and
had only two rounds, with a substantial drop off be-
tween rounds 1 and 2. Unlike other implementations of
a Delphi study, a scoring system was not used to rank
topics [13], nor was a formalised definition of consensus
[14] used, as reflected in the more informal determin-
ation of consensus in this application.
The scope of some of the stages was purposely limited
due to time and resource constraints. The journals
searched for methodological developments were those
thought to be most likely to publish new developments.
It is possible that other developments have been pub-
lished in other journals, which would have potentially
been missed. Consulted stakeholders were predomin-
antly based in the UK and the engagement sessions were
limited in number and dependent upon acceptance of
the proposal at the respective stakeholder meetings.
Conclusions
The DELTA2 project identified a number of areas (such
as practical recommendations and examples, greater
coverage of alternative trial designs and statistical ap-
proaches) of particular interest amongst stakeholders,
which the new guidance was designed to meet. Such
findings influenced both the scope and drafting of the
DELTA2 guidance document. Impact can be seen by the
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substantial changes in the document between the first
and final versions. It is hoped that this process has led
to a more useful and practical document.
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